Head-to-head evidence
Foritinib succinate vs XZP-3621
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ALK / ROS1 · full Non-Small Cell Lung Cancer pipeline
Foritinib succinate
Developed by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
XZP-3621
Developed by Xuanzhu Biopharmaceutical
NCT05204628 · Phase 3 · status unknown
Patients were randomly assigned to XZP-3621 or crizotinib, but the study is open-label rather than blinded, which is a weaker design even though it measures a hard clinical outcome, progression-free survival, against an active standard-of-care comparator. Results have not been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Foritinib succinate's landscape · XZP-3621's landscape